|
|
|
| Association of SYNM GALNT7 and FOXF2 Expression with Clinicopathological Features and Prognosis in Prostate Cancer Tissues |
| LI Shuhao, et al |
| Medical College, Wuhan University of Science and Technology, Hubei Wuhan 430081, China |
|
|
|
|
Abstract Objective: To investigate the association of tissue-linked mitogenin (SYNM), N-acetylaminogalactosyltransferase 7 (GALNT7), and forkhead box transcription factor F2 (FOXF2) expression with clinicopathological features and postoperative prognosis in patients with prostate cancer (PC). Methods: A total of 112 cases of PC patients who underwent radical prostatectomy at CR WISCOM General Hospital affiliated to Wuhan University of Science and Technology from March 2020 to September 2021 were selected as study subjects; clinicopathological features such as age, clinical stage, lymph node metastasis, tumour diameter, Gleason score and so on were recorded; samples of cancer tissues and their paracancerous normal tissues of the PC patients were collected after the operation, and immunohistochemistry was used to detect SYNM, GALNT7, FOXF2 expression in the tissues; the relationship between SYNM, GALNT7, FOXF2 expression and clinicopathological characteristics of PC patients was analysed; three years of postoperative follow-up was conducted to record the survival of PC patients, and the factors affecting the postoperative prognosis of PC patients were analysed by unifactorial and multifactorial Cox regression; the SYNM was analysed by Kaplan-Meier curve, GALNT7, FOXF2 expression in relation to 3-year survival of PC patients. Results: SYNM was mainly expressed in the cytoplasm, GALNT7 was expressed in both the cell membrane and cytoplasm, and FOXF2 was mainly localised in the nucleus. The negative rate of SYNM in the observation group was 82.14% (92/112), which was significantly higher than that of the control group [11.61% (13/112)], χ2=111.883, P＜0.001); the positive rate of GALNT7 in the observation group was 85.71% (96/112), which was significantly higher than that of 4.46% (5/112) in the control group (χ2=149.315, P<0.001); the negative rate of FOXF2 in the observation group was 80.36% (90/112), which was significantly higher than that of 16.07% (18/112) in the control group (χ2=92.690, P<0.001). Among the PC patients, those with late clinical stage, lymph node metastasis, large tumour diameter, high Gleason score and high preoperative PSA level had significantly higher SYNM-negative rate, GALNT7-positive rate, and FOXF2-negative rate than those with early clinical stage, no lymph node metastasis, small tumour diameter, low Gleason score, and low preoperative PSA level (P<0.05). The prognostic death of PC patients was not related to age and clinical stage (P<0.05), but was related to tumour diameter, preoperative PSA level, Gleason score, and lymph node metastasis (P<0.05); preoperative PSA level, Gleason score, negative expression of SYNM, GALNT7-positive expression, and FOXF2-negative expression were all significant influencing factors for death within 3 years in PC patients (P<0.05); the 3-year survival rate was significantly higher in patients with SYNM-positive expression than in patients with negative expression (χ2= 24.633, P<0.05). The 3-year survival rate in patients with GALNT7-negative expression was higher than in patients with positive expression (χ2= 16.453, P<0.05). The 3-year survival rate of patients with positive expression of FOXF2 was significantly higher than that of patients with negative expression (χ2=24.977, P<0.05). Conclusion: The expression of SYNM, GALNT7, and FOXF2 in the tissues of PC patients is closely related to clinical stage, lymph node metastasis, tumor diameter, Gleason score, and preoperative PSA level. Negative expression of SYNM and FOXF2, and positive expression of GALNT7 are important factors affecting the postoperative prognosis of PC patients.
|
|
|
|
|
|
[1] Sekhoacha M,Riet K,Motloung P,et al.Prostate cancer review:genetics,diagnosis,treatment options,and alternative approaches[J].Molecules,2022,27(17):5730.
[2] Liu Y,Sun Y,Xiao M,et al.Comprehensive pan-cancer analysis reveals the versatile role of GALNT7 in epigenetic alterations and immune modulation in cancer[J].Heliyon,2024,10(11):31515.
[3] 李鸿斌,贺宝忠,侯琳,等.KMT2D在前列腺癌患者中的表达及其与临床病理特征和预后的关系[J].疑难病杂志,2023,22(4):373-376,382.
[4] 郑炜智,刘炳辉,盛玲玲,等.SYNM、ALDH1、Galectin–3在大肠癌中的表达及相关性研究[J].中国现代医生,2022,60(24):14-18.
[5] Su Z,Wang G,Li L.CHRDL1,NEFH,TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer[J].Cancer Biomark,2023,38(2):143-159.
[6] Masone MC.The role of GALNT7 as a potential diagnostic marker in prostate cancer[J].Nat Rev Urol,2023,20(4):198.
[7] 张正攀,周新明,冯珍珍,等.肺癌组织中GALNT7的表达变化及其临床意义[J].临床肿瘤学杂志,2024,29(2):131-136.
[8] He W,Kang Y,Zhu W,et al.FOXF2 acts as a crucial molecule in tumours and embryonic development[J].Cell Death Dis,2020,11(6):424.
[9] Jia D,Zhou Z,Kwon OJ,et al.Stromal FOXF2 suppresses prostate cancer progression and metastasis by enhancing antitumor immunity[J].Nat Commun,2022,13(1):6828. |
|
|
|
2025, Vol. 31 
